Sugi Predict

Sugi Predict / Compounds / SCHEMBL4688294

SCHEMBL4688294

SCHEMBL4688294

O=C(OCc1ccccc1)N1CCN(c2cc[c]cc2F)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPSR1 Q6W5P4 2/20 0.51
▸ KMT2A Q03164 2/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ NPC1 O15118 4/20 0.50
▸ SMN1; SMN2 Q16637 4/20 0.50
▸ RAB9A P51151 3/20 0.50
▸ MAPT P10636 2/20 0.49
▸ GRM5 P41594 2/20 0.49
▸ ALOX15 P16050 2/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ LMNA P02545 1/20 0.49
▸ HPGD P15428 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ MAPK1 P28482 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.49
▸ CYP2C19 P33261 1/20 0.48
▸ TMEM97 Q5BJF2 3/20 0.47
▸ SIGMAR1 Q99720 3/20 0.47
▸ L3MBTL1 Q9Y468 3/20 0.45
▸ DPP4 P27487 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7143248 0.86 KMT2A (0.62) NPSR1KMT2AMEN1NPC1SMN1; SMN2
SCHEMBL20521279 0.82 MAPT (0.58) NPSR1KMT2AMEN1NPC1SMN1; SMN2
SCHEMBL13756985 0.80 MAPT (0.56) NPSR1KMT2AMEN1NPC1SMN1; SMN2
SCHEMBL19212037 0.80 MAPT (0.56) NPSR1KMT2AMEN1NPC1SMN1; SMN2
SCHEMBL12073124 0.80 GRM5 (0.58) NPSR1KMT2AMEN1NPC1SMN1; SMN2
SCHEMBL8647978 0.79 PTGDR2 (0.58) NPSR1KMT2ANPC1MAPTGRM5
SCHEMBL4814264 0.79 MEN1 (0.76) NPSR1KMT2AMEN1NPC1SMN1; SMN2
SCHEMBL7393652 0.79 MEN1 (0.76) NPSR1KMT2AMEN1NPC1SMN1; SMN2
SCHEMBL3970912 0.79 MEN1 (0.76) NPSR1KMT2AMEN1NPC1SMN1; SMN2
SCHEMBL379160 0.79 MEN1 (0.76) NPSR1KMT2AMEN1NPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1114819-B1 Process to prepare oxazolidinones PHARMACIA & UPJOHN CO LLC (US) 2008-01-09 — — EP claimed
EP-1028940-B1 PROCESS TO PRODUCE OXAZOLIDINONES PHARMACIA & UPJOHN CO LLC (US) 2007-04-18 — — EP claimed
EP-1772453-A1 Process to produce Oxazolidinones Pharmacia & Upjohn Company LLC (US) 2007-04-11 — — EP claimed
EP-1328509-B1 METHODS OF PRODUCING OXAZOLIDINONE COMPOUNDS PHARMACIA & UPJOHN CO LLC (US) 2006-03-22 — — EP claimed
US-6833453-B2 As an example, manufacturing a 5-(tert-butylcarbamoyl)-amino-methyl-oxazolidinone by condensing a carbamate with a tert-butylcarbamoyl protected derivative of glycidylamine or a 3-amino-1-halopropanol PHARMACIA & UPJOHN COMPANY 2004-12-21 — — US claimed
US-20040143131-A1 in particular,manufacturing a 5-(tert-butylcarbamoyl)-aminomethyl-oxazolidinone by condensing a carbamate with a tert-butylcarbamoyl protected derivative of glycidylamine or 3-amino-1-halopropanol, intermediates PHARMACIA & UPJOHN COMPANY 2004-07-22 — — US claimed
US-6740754-B2 CYCLIZATION OF CARBAMATE WITH SECONDARY ALCOHOL, EPOXIDE OR ESTER REACTANT PHARMACIA & UPJOHN COMPANY 2004-05-25 — — US claimed
US-6716980-B2 CYCLIZATION AND ACYLATION OF CARBAMATE PHARMACIA & UPJOHN COMPANY 2004-04-06 — — US claimed
US-20040006238-A1 Process to produce oxazolidinones PHARMACIA & UPJOHN COMPANY 2004-01-08 — — US claimed
US-20030216572-A1 PROCESS TO PRODUCE OXAZOLIDINONES PHARMACIA & UPJOHN COMPANY 2003-11-20 — — US claimed
US-20020086900-A1 Methods of producing oxazolidinone compounds PERRAULT WILLIAM R (US) 2002-07-04 — — US claimed
WO-2002032857-A1 METHODS OF PRODUCING OXAZOLIDINONE COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2002-04-25 — — WO claimed
US-6362334-B1 OXAZOLIDINONE PHTHALAMIDE PHARMACIA & UPJOHN COMPANY 2002-03-26 — — US claimed
US-20020032348-A1 Process to produce oxazolidinones PEARLMAN BRUCE ALLEN (US) 2002-03-14 — — US claimed
EP-1114819-A1 Process to prepare oxazolidinones PHARMACIA & UPJOHN COMPANY (US) 2001-07-11 — — EP claimed
EP-1028940-A1 PROCESS TO PRODUCE OXAZOLIDINONES PHARMACIA & UPJOHN COMPANY (US) 2000-08-23 — — EP claimed
WO-1999024393-A1 PROCESS TO PRODUCE OXAZOLIDINONES PHARMACIA & UPJOHN COMPANY (US) 1999-05-20 — — WO claimed
CN-1215393-A Process for preparing oxazolidinones UPJOHN CO (US) 1999-04-28 — — CN claimed
EP-0892792-A1 PROCESS TO PREPARE OXAZOLIDINONES PHARMACIA & UPJOHN COMPANY (US) 1999-01-27 — — EP claimed
WO-1997037980-A1 PROCESS TO PREPARE OXAZOLIDINONES PHARMACIA & UPJOHN COMPANY (US) 1997-10-16 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040143131-A1 in particular,manufacturing a 5-(tert-butylcarbamoyl)-aminomethyl-oxazolidinone by condensing a carbamate with a tert-butylcarbamoyl protected derivative of glycidylamine or 3-amino-1-halopropanol, intermediates TET1, NAT10, TET3 NPSR1 4781/4885KMT2A 1744/4885MEN1 3212/4885
US-20040006238-A1 Process to produce oxazolidinones ADH1A, ADH5, ADH1C NPSR1 1699/4885KMT2A 913/4885MEN1 3693/4885
US-20030216572-A1 PROCESS TO PRODUCE OXAZOLIDINONES ADH1A, ADH5, ADH1C NPSR1 1993/4885KMT2A 783/4885MEN1 3842/4885
US-20020086900-A1 Methods of producing oxazolidinone compounds TET3, TET1, AZI2 NPSR1 4462/4885KMT2A 2048/4885MEN1 2766/4885
US-20020032348-A1 Process to produce oxazolidinones ADH1A, ADH5, ADH1C NPSR1 1993/4885KMT2A 783/4885MEN1 3842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.